Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction by Bhatti, Maria et al.
Accepted Manuscript
Effect of Bruton's tyrosine kinase inhibitors on platelet
aggregation in patients with acute myocardial infarction
Maria Bhatti, Sarah Ayton, Olga Michail, Nicholas D. Gollop,
Alisdair Ryding, Stuart Rushworth, Kristian Bowles, Tobias
Geisler, Marcus Flather
PII: S0049-3848(19)30217-8
DOI: https://doi.org/10.1016/j.thromres.2019.04.024
Reference: TR 7351
To appear in: Thrombosis Research
Received date: 30 December 2018
Revised date: 23 March 2019
Accepted date: 23 April 2019
Please cite this article as: M. Bhatti, S. Ayton, O. Michail, et al., Effect of Bruton's tyrosine
kinase inhibitors on platelet aggregation in patients with acute myocardial infarction,
Thrombosis Research, https://doi.org/10.1016/j.thromres.2019.04.024
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 1 
Title Page 
Manuscript Title: Effect of Bruton’s Tyrosine Kinase inhibitors on platelet 
aggregation in patients with Acute Myocardial Infarction 
 
Author List: 
Maria Bhatti1, Sarah Ayton1, Olga Michail1, Nicholas D. Gollop1, Alisdair Ryding2, 
Stuart Rushworth1, Kristian Bowles1,2, Tobias Geisler3, Marcus Flather1,2 
1Norwich Medical School, University of East Anglia and Norfolk and Norwich 
University Hospital, Norwich, Norfolk, United Kingdom 
2Norfolk and Norwich University Hospital, Colney Lane, Norwich, Norfolk, United 
Kingdom 
3Department of Cardiology, University Hospital Tübingen, Tübingen, Germany. 
 
Corresponding author: Professor Marcus Flather, m.flather@uea.ac.uk  
Postal address: Norwich Medical School, University of East Anglia, Norwich 
Research Park, Norwich, Norfolk, United Kingdom, NR4 7TJ 
Telephone number: +441603 592963 
 
Total word count: 2319 
 
All authors have read and agreed with the submission of the manuscript.   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 2 
Abstract  
Aims: Despite widespread use of dual antiplatelet therapy in acute myocardial 
infarction, there remains a residual risk of morbidity and mortality. Bruton’s Tyrosine 
Kinase inhibitors have been found to inhibit platelet aggregation through the 
Glycoprotein VI collagen-mediated pathway. The Bruton’s Tyrosine Kinase inhibitor, 
Ibrutinib is used in the management of haematological malignancies and another 
Bruton’s Tyrosine Kinase inhibitor, ONO-4059 (also known as tirabrutinib), is in 
clinical development. This is an observational study to evaluate the effects of 
Ibrutinib and ONO-4059 on platelet aggregation after acute myocardial infarction. 
Methods and Results: Twenty patients with a confirmed diagnosis of acute 
myocardial infarction were enrolled and blood samples obtained within 48 hours of 
hospital admission. All patients were on dual antiplatelet therapy; aspirin plus a 
P2Y12 inhibitor (clopidogrel or ticagrelor). Blood samples were treated ex vivo with 
increasing concentrations of Ibrutinib (0, 0.5, 1, 2µM) and ONO-4059 (0, 0.2, 0.5, 
1µM). Platelet aggregation was measured in response to collagen using a Multiplate 
analyser to estimate the area under the curve, with lower values indicating lower 
platelet aggregation. The median age was 63 years and 80% were male. The 
median area under the curve values for Ibrutinib concentrations 0 (control), 0.5, 1 
and 2mmol/l were 18.5, 8 (P=0.0004), 4.5 (P<0.0001) and 2 (P<0.0001) units and for 
ONO-4059 concentrations 0 (control), 0.2, 0.5 and1µM, median area under the curve 
values were 13, 12 (P=0.7), 6.5 (P=0.0001) and 5.5 (P=0.0004 compared to control).  
Conclusion: The Bruton’s Tyrosine Kinase inhibitors, Ibrutinib and ONO-4059, show 
further inhibition of platelet aggregation in blood samples from patients with acute 
myocardial infarction, receiving dual antiplatelet therapy in a dose dependent 
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manner. These results provide a rationale for Bruton’s Tyrosine Kinase inhibitors to 
be tested as a potential new antiplatelet strategy for acute myocardial infarction. 
 
Keywords: Ibrutinib; Acute myocardial infarction; Bruton's Tyrosine Kinase Inhibitor; 
Tyrosine Kinases; platelet aggregation  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 4 
1. Introduction 
Dual antiplatelet therapy, with aspirin and a P2Y12 inhibitor (commonly, clopidogrel 
or ticagrelor), is a cornerstone of the long-term management of acute myocardial 
infarction (MI). [1-3] Despite its widespread use, there is a 15% risk of death or 
recurrent events at 12 months, and 8% of acute MI patients are readmitted within 
one month of an acute episode. [4] This suggests there is scope for development of 
anti-platelet therapies which act via alternative pathways. 
 
Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, which is licensed for the 
treatment of chronic lymphocytic leukaemia (CLL), Mantle Cell Lymphoma (MCL) 
and lymphocytic lymphoma and exerts its therapeutic effect by disrupting malignant 
B-cell function and survival. [5-8] With long-term follow up, more than half of patients 
on Ibrutinib experienced a bleeding event [9,10] and the pooled relative risk of the 
occurrence of any bleeding with Ibrutinib is 2.72. [11] The majority of bleeds are 
cutaneous in nature and there is a low occurrence of major bleeding. [8] In-vitro and 
ex-vivo studies have found Ibrutinib significantly inhibits platelet aggregation in 
response to collagen. [12-14] Ibrutinib irreversibly inhibits BTK and Tec, both of 
which are non-receptor tyrosine kinases involved in platelet aggregation, via the 
Glycoprotein VI (GPVI) collagen mediated pathway. [15,16] This pathway is not 
currently targeted in the management of acute MI.  
 
Several other BTK inhibitors are in clinical development stages. [17] ONO-4059 (also 
known as tirabrutinib) is an irreversible selective inhibitor of BTK, which in a Phase I 
trial of 90 patients with relapsed/refractory B-cell malignancies had a lower incidence 
of associated toxicities compared to Ibrutinib. [18,19] 
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We hypothesise that the BTK inhibitors, Ibrutinib and ONO-4059, could have 
additional therapeutic antiplatelet activity in patients with acute MI. This study aimed 
to assess the ex-vivo effects of Ibrutinib and ONO-4059 on platelet aggregation in 
blood samples obtained from patients with acute MI treated with dual antiplatelet 
therapy.   
 
2. Method 
2.1. Study Design 
Single-centre, observational, prospective study approved by a national accredited 
Research Ethics Committee and conducted according to the ethical guidelines of the 
Declaration of Helsinki and Good Clinical Practice. All patients provided written 
informed consent prior to participation.  
 
2.2. Subject Selection and Recruitment 
Patients with acute MI were recruited between March and July 2016. Inclusion 
criteria were individuals aged >18 years with a clinical diagnosis of acute MI with 
elevated serum troponin, with or without electrocardiogram (ECG) changes of 
myocardial ischaemia (+/-ST elevation). Exclusion criteria were participation in 
another research study and difficult venepuncture.  
 
2.3. Blood sample collection and analysis  
A single venous blood sample was collected in a Hirudin vacutainer (Roche, UK) 
between 24 and 48 hours of hospital admission. Blood samples were immediately 
analysed. Blood samples were treated with 0.5, 1 and 2µM of Ibrutinib and with 0.2, 
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0.5, 1µM of ONO-4059. A control sample (0µM) was also tested alongside each 
inhibitor. The concentrations used were determined through preliminary investigation 
carried out in healthy volunteers. Accuracy of platelet aggregation is subject to time 
delays between collection and analysis, therefore as only 4 samples could be 
analysed at one time, a 1-hour incubation period was used for Ibrutinib and 30 
minutes for ONO-4059. All concentrations of Ibrutinib were analysed simultaneously 
for each patient, as were all concentrations of ONO-4059. Ibrutinib and ONO-4059 
were purchased from Selleck Chemicals (USA). They were dissolved in dimethyl 
sulfoxide (DMSO) and diluted in phosphate buffered saline (PBS). Platelet 
aggregation in response to 20µl of collagen (Roche, UK), which equates to a final 
concentration of 3.2 μg/mL, was measured using a multiplate analyser (Roche, UK) 
in accordance with manufacturer’s guidelines. As platelets bind to the multiplate 
sensors, there is an increase of impedance and this is transformed into an 
Aggregation Unit. The aggregation unit is then plotted against time. The overall 
platelet activity is measured by calculating the area under the curve (AUC).  
 
2.4. Statistical analysis 
This was an observational pilot study, so no formal sample size calculations were 
undertaken. Baseline characteristics are reported as percentages of the study 
population. Normally distributed baseline characteristics are reported as means with 
standard deviations. Non-normally distributed baseline characteristics are reported 
as medians with interquartile ranges. For each concentration of Ibrutinib and ONO-
4059 the median AUC with interquartile ranges is given. Lower AUC values indicate 
less platelet aggregation. Comparisons between control (0µM) and samples treated 
with Ibrutinib and ONO-4059 were done with Wilcoxon signed rank test as the data 
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were not normally distributed. A p-value of p<0.05 was considered to be statistically 
significant.  
 
 
3. Results 
22 participants were enrolled and two participants were excluded due to non-MI 
diagnosis at discharge. Of the 20 participants included in the final analysis, 6 
patients did not have blood samples treated with ONO-4059, as early in the study 
the doses were adjusted for this inhibitor.  
 
Baseline characteristics are shown in Table 1. The mean age of participants was 
63.2± 11.4 years and 80% of participants were male. All patients received dual 
antiplatelet therapy, with aspirin (300mg loading dose and 75mg maintenance) and a 
P2Y12 inhibitor (30% received clopidogrel and 75% ticagrelor; three patients 
received both Clopidogrel and Ticagrelor whilst in hospital; Clopidogrel was given as 
a loading dose and subsequently switched to Ticagrelor whilst in hospital). 
Participants also received a beta-blocker, angiotensin-converting enzyme 
inhibitor/angiotensin II receptor blocker (ACEi/ARB) and a statin. Three patients 
received GPIIIa/IIb inhibitors during admission.  
 
Table 1: Baseline Characteristics 
Characteristic n (%) (n=20) 
Age (years, mean ± SD) 63.2 ± 11.4 
Male 16 (80) 
Current smoker 5 (25) 
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Family history of CAD (n=19) 12 (63) 
Diabetes 1 (5) 
Hypertension 7 (35) 
Hypercholesterolaemia 9 (45) 
History of CAD 5 (25) 
NSTEMI 14 (70) 
STEMI 6 (30) 
Inpatient coronary angiography 18 (90) 
Site of infarct 
Anterior 5 (25) 
Inferior 5 (25) 
Anterolateral 2 (10) 
Indeterminate 5 (25) 
Inferior Posterior 1 (5) 
Lateral 2 (10) 
Medication given during hospitalisation 
Aspirin 20 (100) 
Clopidogrel 6 (30) 
Ticagrelor 15 (75) 
Beta-blocker 15 (75) 
ACEi 16 (80) 
ARB 2 (10) 
Diuretics 1 (5) 
Aldosterone 1 (5) 
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Glycoprotein IIb/IIIa inhibitors 3 (15) 
Statin 19 (95) 
Peak Troponin I level (ng/L) 
median (IQR) 1101.5 (275 – 7112.75) 
Platelet count (109/L) 
median (IQR) 242 (199.5 - 287.25) 
ACEi = angiotensin coverting enzyme inhibitor, ARB = angiotensin receptor blocker, 
CAD = coronary artery disease, IQR = interquartile range, NSTEMI = Non ST-
elevation myocardial infarction, SD = standard deviation, STEMI = ST-elevation 
myocardial infarction 
 
For Ibrutinib concentrations of 0, 0.5, 1, 2µM, the median (IQR) AUC for platelet 
aggregation were 18.5 (7 – 29.25), 8 (2.5 – 18.75), 4.5 (1 – 15.75) and 2 (0 – 10.5) 
(P value of 0.0004, <0.0001 and <0.0001 respectively compared to control: Figure 
1). For ONO-4059 concentrations of 0, 0.2, 0.5, 1µM, the mean (IQR) platelet 
aggregation was 13 (7 – 23.5), 12 (8.75 – 22.25), 6.5 (2.75 – 14.25), 5.5 (2.5 – 9.25) 
(p values 0.7, 0.0001 and 0.0004 respectively compared to control: Figure 2). 
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Figure 1: Platelet aggregation was measured using a Multiplate analyser 
(collagen agonist concentration 3.2 μg/mL)  with ex-vivo addition of increasing 
doses of Ibrutinib in blood samples from patients with acute myocardial 
infarction treated with dual anti-platelet therapy (n=20) Each circle represents 
individual data points, with horizontal lines representing median values, with lower 
and upper quartiles. Wilcoxon signed rank test was carried out to compare 0µM 
(control) with 0.5, 0.1 and 0.2µM of Ibritunib.  
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Figure 2: Platelet aggregation was measured using a Multiplate analyser 
(collagen agonist concentration 3.2 μg/mL) with ex-vivo addition of increasing 
doses of ONO-4059 in blood samples from patients with acute myocardial 
infarction treated with dual anti-platelet therapy (n=14) Each circle represents 
individual data points, with horizontal lines representing median values, with lower 
and upper quartiles. Wilcoxon signed rank test was carried out to compare 0µM 
(control) with 0.2, 0.5 and 1µM of ONO-4059. 
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4. Discussion 
The BTK inhibitors Ibrutinib and ONO-4059 provide dose dependent inhibition of 
platelet aggregation in ex-vivo samples from patients with acute MI already treated 
with dual antiplatelet therapy.  
 
Rushworth et al. [14] analysed platelet aggregation in blood samples obtained from 
patients with CLL/MCL treated with Ibrutinib to investigate the in-vitro effect of 
Ibrutinib on platelet function. Platelet aggregation in response to collagen was 
significantly inhibited while platelet aggregation in response to ADP was also 
inhibited, but to a lesser extent. Platelet aggregation in response to Arachidonic Acid 
and Thrombin Related-activated Peptide (TRAP) was not inhibited. Levade et al. [12] 
incubated healthy donor blood with Ibrutinib and demonstrated that Ibrutinib inhibits 
collagen induced platelet aggregation in a dose dependent manner with higher 
doses being associated with lower maximum platelet aggregation. Kamel et al. [13] 
and Levade et al. [12] demonstrated that platelet aggregation in response to collagen 
was inhibited in patients receiving Ibrutinib for CLL/MCL, but not in response to ADP, 
Arachidonic acid, adrenaline, ristocetin, and U46619 (thromboxane A2). Patients 
with CLL/MCL with bleeding complications on Ibrutinib were found to have 
significantly lower platelet aggregation compared to those without evidence of 
bleeding. [13] More recently, Nicolson and colleagues report that inhibition of BTK 
kinase actually causes only partial inhibition of GPVI signalling in platelets and they 
provide evidence that BTK supports GPVI signalling by functioning as an adapter 
protein as well as a kinase. [20] Taken together, these findings support the 
hypothesised role of BTK in GPVI collagen mediated pathway in platelets and our 
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findings provide further evidence of this in patients with acute MI receiving dual 
antiplatelet therapy.   
In the study by Kamel et al., the majority of patients received 420mg of Ibrutinib 
daily. [13] Pharmacokinetic and pharmacodynamics studies suggest in-vivo plasma 
concentration of 0.4µM is achieved with a once daily dose of 560mg; [21, 22] a 
420mg dose of Ibrutinib is likely to have a lower plasma concentration. Our results 
show inhibition of platelet aggregation with Ibrutinib at a concentration of 0.5µM 
which could be achieved with current therapeutic doses.  The exact doses to be 
tested in potential future studies in acute MI remain to be determined.  
 
Ibrutinib acts via BTK and Tec expressed in platelets, both of which are non-receptor 
tyrosine kinases belonging to the Tec family kinases (TFK). [15, 16] Inhibition of BTK 
and Tec interferes with the downstream signalling of the GPVI collagen mediated 
pathway. Platelet adhesion, an initial step in thrombus formation, occurs when GPVI 
binds to exposed collagen. This leads to PI3K dependent phosphorylation of BTK 
and Tec. These then in turn activate PLCy2. [15, 23] Ibrutinib treated platelets have 
reduced phosphorylation of PLCy2 and autophosphorylation of BTK. [12] Ibrutinib 
therapy also affects other pathways involved with platelet aggregation, including 
platelet activation by von Willebrand factor (vWF), reducing platelet adhesion onto 
vWF with high shear rate. [12] Additionally, BTK is essential in GPIb dependent 
thrombus formation [24] and is involved in activation of platelets via C-type lectin-like 
receptor-2 (CLEC-2). [25] BTK and Tec also appear to be involved in the later stages 
of thrombus formation via the fibrinogen receptor integrin αIIbβ3, which leads to 
phosphorylation of the two tyrosine kinases. [26,27] 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 14 
Animal models of GPVI-deficiency have demonstrated potential protection against 
platelet activation, adhesion and thrombus formation at sites of vascular injury. [28-
30] Increased GPVI expression has been linked to patients with acute MI, which may 
suggest GPVI inhibition could be beneficial. [31] Studies targeting GPVI are 
underway in stable coronary artery disease. [32,33] 
 
Collagen exposed on atherosclerotic plaques is morphologically different to collagen 
within physiological tissue. [34,35] Busygina et al. explored the in-vitro and ex-vivo 
effects of Ibrutinib and ONO-4059 on platelet aggregation in response to 
atherosclerotic plaque material and native collagen fibres, in static and high shear 
arterial flow conditions. Both BTK inhibitors inhibited platelet aggregation in response 
to plaque derived collagen and native collagen under static conditions, however with 
high shear arterial flow platelet aggregation was impaired with plaque material, but 
not with native collagen fibres. [36] This suggests that Ibrutinib and ONO-4059 may 
be advantageous in atherosclerotic disease by inhibiting thrombus formation on 
atherosclerotic plaques while sparing physiological platelet function.  
 
4.1. Limitations 
This was an exploratory ex-vivo study with a small sample size, therefore the results 
cannot be extrapolated to the use of these agents in a clinical setting. This study 
cannot provide any reliable information on safety aspects of BTK inhibitors, including 
risk of bleeding, (or other reported side effects such as thrombocytopenia, 
neutropenia and increased risk of infection) given in the context of acute MI where 
other antithrombotic treatments are also given.  All these potential side effects would 
need to be carefully assessed before BTK inhibitors could be used as a treatment 
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acute MI.  In this study we only measured platelet aggregation in response to 
collagen, whereas BTK inhibitors may have other mechanisms of inhibition 
particularly in the context of acute MI and routinely administered antiplatelet therapy, 
which could be explored in future studies. Measurement of platelet aggregation is 
subject to a number of influences that need to be carefully controlled and results can 
be affected by factors such as smoking on the day of testing, shaking or mixing of 
blood and the time between obtaining sample and analysis. Samples were 
transported and analysed as soon as possible and the estimated average time from 
obtaining blood samples to analysis was 70 minutes. This was in keeping with 
recommendations for collection, transport and analysis for measurement of platelet 
aggregation. [37] 
4.2. Conclusion 
We have demonstrated that the BTK inhibitors Ibrutinib and ONO-4059 show dose 
dependent inhibition of platelet aggregation, at physiologically relevant 
concentrations, in blood samples taken from patients with acute MI on dual 
antiplatelet therapy. These preliminary observations support further exploration of 
BTK inhibitors as potential therapeutic antiplatelet agents for coronary artery disease 
through the GPVI collagen pathway, which is not utilised in current anti-platelet 
regimens. 
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Highlights 
 
Ref.:  Ms. No. TR-D-18-00983 
Effect of Bruton's Tyrosine Kinase inhibitors on platelet aggregation in patients with 
Acute Myocardial Infarction 
 
 Bruton’s tyrosine kinase inhibitors affect the glycoprotein VI collagen pathway 
 They add further platelet inhibition in blood samples after myocardial infarction 
 This provides a rationale for clinical testing as potential new antiplatelet 
agents 
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